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emerged as a specific subset of cells that significantly contribute to the development of autoimmune inflammatory diseases [3, 4] .
Th17 cells were named after the cytokine they produce, IL-17, whose pleiotropic activities include the induction of proinflammatory cytokines TNF, IL-1, and IL-6, as well as chemokines like IL-8 and monocyte chemoattractant protein 1(MCP1) in various cell types [5] , [6] . Studies using IL-17 or IL-17 receptor (IL-17R) knock-out mice have highlighted the key role of this cytokine in several animal models of autoimmune diseases including collagen-induced arthritis [7] , experimental autoimmune encephalomyelitis [8] , experimental colitis [9, 10] and allergic asthma [11] .
The clinical relevance of these findings has been confirmed by a number of studies showing for instance the presence of IL-17 in the synovial fluid of patients with rheumatoid arthritis (RA) [12, 13] , the production of this cytokine by T cell clones established from RA patients [14, 15] and the expression of IL-17 mRNA in mononuclear cells present in the cerebrospinal fluid of multiple sclerosis patients [16] . These "by-the-day" growing number of evidences on the role of IL-17 in chronic inflammatory diseases have surely established the importance of this cytokine in autoimmunity. However, very little is still known on the biological effects promoted by this cytokine in vivo.
Therefore, in this study, we set out to investigate and characterize the effects of IL-17 in two classical models of inflammation reasoning that this would expand our knowledge on the pathological role of this cytokine and at the same time provide information on experimental models that could be helpful to develop novel anti-IL-17 strategies. 4
Materials and methods

Reagents
Recombinant mouse IL-17 and anti-mouse KC antibody (clone 48415) were purchased from R&D System (Abingdon, UK) and dissolved in carboxymethylcellulose (CMC 0.5% w/v in sterile PBS). -carragenan (1% w/v) was dissolved in sterile PBS. Unless otherwise specified, all the other reagents were from Sigma-Aldrich Co (Dorset, UK).
Mice
Male C57BL/6 mice (24 to 28 g; Harlan, UK) were used for all experiments. Animals were kept under standard conditions and maintained in a 12h/12h light/dark cycle at 22 ± 1°C in accordance with United Kingdom Home Office regulations (Guidance on the Operation of Animals, Scientific Procedures Act 1986) and of the European Union directives.
Paw oedema
Male C57BL/6 mice were divided into groups of 7, lightly anaesthetized with enflurane 4% Oedema, measured with a hydropletismometer (Ugo Basile, Milan, Italy), was calculated by subtracting the initial paw volume to the paw volume measured at each time point.
Myeloperoxidase assay
Leukocyte myeloperoxidase (MPO) activity was assessed by measuring the H 2 O 2 -dependet oxidation of 3,3',5,5'-tetramethylbenzidine (TMB) as previously reported [17] . Paw tissues were homogenized for 35 sec in a solution composed of hexadecyltrimethylammonium bromide (HTAB; 0.5% w/v) in 50 mM sodium phosphate buffer pH 5.4 using Precellys 24 ceramic beads (Bertin technologies, France). After homogenization, samples were centrifuged (4000 g) for 20 min and the supernatants collected and used for the assay.
Aliquots of 20µl were incubated with 160 l of TMB and 20 l of H 2 O 2 (in 80 mM phosphate buffer, pH 5.4) in 96-well plates. Plates were incubated for 5 min at room temperature and optical density was read at 620nm using GENios (Tecan, Reading, UK).
Assay were performed in duplicates and normalized for protein content.
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Airpouch
Dorsal airpouches were prepared by injection of 2.5 ml of air on day 0 and day 3. On day 6, mice received IL-17 (0.1, 0.5 or 1.0 µg) in 0.5 ml of 0.5% CMC, or CMC alone, directly into the pouch, modifying a protocol optimised for the response to IL-1 [18] . In some experiments IL-17 (1.0 µg) was co-injected with 10 µg of neutralizing anti-KC antibody [19] . Mice were sacrificed at different time-points, and airpouches washed thoroughly with 2 ml of PBS containing 50 U/ml heparin and EDTA (3 mM). Lavage fluid were centrifuged at 220g for 10 min at 4°C to separate the exudates from the inflammatory cells. Inflammatory exudates were collected and measured to evaluate the total volume and the protein concentration as index of plasma leakage. Protein concetration was determined using Biorad Protein Assay (Bio-Rad Laboratories, Hemel Hempstead, UK) according to the manufacturer's instructions. Total and differential cell counts were performed by light microscopy after staining in Turk's solution (crystal violet 0.01 % in 3% acetic acid).
Flow cytometry
Cells collected from the pouch cavities were washed with PBS and resuspended in FACS 
Histology
Histological analyses were conducted at the 6 h time-point: joints were trimmed, placed in decalcifying solution (EDTA 0.1mM in PBS) for 14 days and then embedded in paraffin.
Sections (5 μm) were deparaffinized with xylene and stained with haematoxylin and eosin (H&E). Airpouch lining tissue samples were cut along the longitudinal axis at approximately the pouch midline, with particular care to preserve the original shape, fixed and embedded in paraffin blocks. Sections (5 μm) were permanently bonded to cover slips and stained with H&E. In all cases, a minimum ≥3 sections per animal were evaluated. Phase-contrast digital images were taken using the Image Pro image analysis software package. anti-sense. Samples were normalised using ribosomal 18S QuantiTect Primer Assay oligonucleotides (QIAGEN).
RT-PCR
Statistical Analysis
Prism software (GraphPad software) was used run analysis of variance (ANOVA), or Student's t-test for two selected groups. P-values lower than 0.05 were considered significant.
Data are presented as mean ± S.E.M of n samples per group. 7
Results
IL-17 does not induce paw inflammation
To investigate the inflammatory properties of IL-17 in vivo we injected increasing doses of recombinant IL-17 (0.1, 0.5 or 1.0g) in the mouse hind paw and monitored changes in paw volume over 72 h, using the response to -carrageenan as positive control. IL-17 produced a very small and non-significant increase in paw volume at 2 h whereas -carrageenan produced typical oedema response, peaking at 6 and 48 h (Figure 1 ). We measured inflammatory leukocyte infiltration at 2 and 6 h measuring MPO activity in paw homogenates and observed similar results: a significant increase in -carrageenan but not IL-17 injected tissues compared to vehicle treated mice (Figure 2A ). Consistent with these findings, H&E staining of -carrageenan-injected paws clearly showed the presence of inflammatory leukocytes ( Figure 2B , right panel) whereas very little cell infiltrates was observed in tissues from mice administered with vehicle or IL-17 ( Figure 2B , left or middle panel, respectively).
IL-17 amplifies on going inflammation
We next tested the effects of recombinant IL-17 in a mouse model of ongoing inflammation, the air pouch, where a lining tissue infiltrated by inflammatory cells forms over 6 days. As shown in Figure 3 , injection of vehicle produced a modest infiltration of cells into the pouch.
In contrast, administration of IL-17 (1μg) produced an intense accumulation of inflammatory cells that peaked at 24 h, declining over 48 h ( Figure 3A ). This effect was accompanied by a similar pattern of accumulation of inflammatory fluid and increase in plasma leakage ( Figure   3B and C, respectively); moreover, this response was dose dependent, with significant differences observed at 0.5 and 1.0 g of IL-17 ( Figure 3D ).
Increased expression of IL-17 receptor in inflamed tissues
We hypothesized that IL-17 induced an inflammatory response in the air pouch but not in the paw because of different levels of expression of IL-17R in these tissues. Consistent with our expectations, we observed a marked and detectable expression of IL-17R mRNA in the naïve air pouch tissues but not in the paw ( Figure 4A 
IL-17 induces a selective pattern of inflammatory cytokines
Next, we investigated whether IL-17 induced a specific pattern of inflammatory cytokine and chemokines. Interestingly, whereas IL-17 induced a significant, yet modest increase in IL-1β levels (around 50-60% at 4-24 h; Figure 8B ), levels of TNF and IL-6 were increased to a much greater extent (~160 and 950%, respectively), and significantly different only at 4 h when compared to vehicle-injected mice ( Figure 8A and C, respectively). Similarly, IL-17
augmented KC levels much more than those of MCP-1 (3-fold vs. ~60%; Figure 8D and E, respectively). No significant differences were observed for levels of IL-2, IL-10, IFN and TGF (data not shown).
The CXC chemokine KC mediates the inflammatory effect of IL-17
To establish if KC levels detected in association with the PMN recruitment induced by IL-17 was functional, a neutralizing anti-KC antibody was co-injected together with IL-17.
Treatment of mice with anti-KC antibody significantly reduced IL-17-induced cell infiltration, exudate accumulation and plasma leakage (Figure 9 A, B and C, respectively).
These effects were paralleled by a similar inhibition of TNF, IL-1 and IL-6 contents detected in the inflammatory exudates (Figure 9 D, E and F, respectively).
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Discussion
Many studies over the last decade have given IL-17 a unique role in the context of the inflammatory response [21, 22] . This cytokine is produced mainly by T cells rather than by macrophages or other cells of the innate immune system and thus it is believed to play an important role in the inflammatory events triggered by the adaptive or memory immune system [23, 24] . In line with this hypothesis, studies in vivo as well as in vitro have suggested that IL-17 cooperates either additively or synergistically with various cytokines or mediators in inducing inflammation [25, 26] . Surprisingly, however, very little is known about the specific effects induced by this cytokine alone. The aim of this study was to investigate if IL-17 could induce an inflammatory response per se or whether it acted predominantly as an amplifier of ongoing inflammation.
We began our study by testing the effects of IL-17 in the mouse paw oedema model, a wellknow experimental system for the study of phlogogenic compounds or testing antinflammatory drugs in vivo [27, 28] . Interestingly, injection of IL-17 into the paw did not induce any significant increases in paw volume or inflammatory leukocyte infiltration. These results were independent of mouse strain (data not shown) and quite surprising since obtained using three different doses that have been reported to cause a significant inflammatory response in other in vitro [29] [30] [31] or in vivo systems [32, 33] . Only few studies have shown that IL-17 induces PMN infiltration in other cavities such as the peritoneum or the lung [32, 38] . In our experiments, the inflammatory response induced by IL-17 in the airpouch was much greater in terms of both cellular infiltrate and cytokine production. Once again this might be explained by the specific reliance of IL-17 on a preinflamed tissue and a 'primed' cellular microenvironment to exert its full potential. It should be in fact considered that both peritoneum and lung are sites under immuno surveillance and,
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as such, under continuous control of the adaptive and innate immune systems. Conversely, the airpouch is a newly formed structure that originates as result of an unrecognized (and by day 6 inflamed) tissue reorganization.
In agreement with this view, original studies on the airpouch have suggested that the inflammatory response that characterize this model partially resembles the inflammatory settings found in the synovium of RA patients [35, 39] . Synovial fluids contain large numbers of PMNs and T cells; it is believed their presence drives destruction and erosion of the joint.
The IL-17 produced locally probably by activated memory T cells as well as by neutrophils might be the key factor for exacerbation of local inflammatory circuits [40, 41] . In conclusion, our results further confirm the role of IL-17 in the exacerbation of the inflammatory response and provide a useful and easier alternative way to test the effect of IL-17-targeted drugs in vivo. Furthermore, we suggest that novel anti-IL-17 compounds might be useful to limit disease progression in autoimmune diseases while ineffective in preventing the acute phase of the inflammatory response.
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